Apeloa Pharmaceutical Co Ltd

Apeloa Pharmaceutical maintains a conservative capital structure with a debt-to-equity ratio of 0.29 and a current ratio of 1.47, indicating adequate short-term liquidity coverage. The company holds total assets of 12.32 billion CNY against total liabilities of 5.98 billion CNY, resulting in total equity of 6.34 billion CNY. Despite positive operating cash flow of 1.22 billion CNY, free cash flow stands at 337.88 million CNY after capital expenditures of 386.21 million CNY. A key risk flag notes that net cash is negative after subtracting total debt, suggesting reliance on debt financing for certain operations despite the low leverage ratio.

Profitability metrics show a return on equity of 16.34% and a return on assets of 8.41%, reflecting efficient use of capital. The company generated net income of 890.68 million CNY on revenue of 9.78 billion CNY, yielding a net margin of approximately 9.1%. Gross profit of 2.49 billion CNY indicates a gross margin of roughly 25.4%, while operating income of 1.07 billion CNY suggests controlled operating expenses. Without cohort median data for direct comparison, these returns appear robust for a pharmaceutical entity, particularly given the moderate valuation multiples.

Segment and geographic revenue breakdowns are not provided in the available data, preventing analysis of revenue concentration or regional exposure. The company’s activity is broadly classified as unclassified within the pharmaceuticals industry, limiting specific insights into product mix or market focus.

Growth trajectory analysis is constrained by the absence of historical period data, preventing year-over-year or quarterly trend evaluation. The latest normalized period shows strong absolute revenue generation, but without prior period comparisons, the direction and sustainability of growth remain unquantified in this snapshot.

Risk assessment highlights medium liquidity risk and low dilution risk, with the primary concern being negative net cash after debt subtraction. The company’s shares outstanding are identical for basic and diluted counts at 1.16 billion, indicating no immediate dilutive securities in the current period. The low dilution risk aligns with the absence of convertible debt or significant option pools impacting the share count.

Recent IR observations indicate strong analyst sentiment, with a mean recommendation of 1.80 (closer to strong buy) and a mean price target of 19.60 CNY, implying upside from the current market price of 18.46 CNY. Analyst coverage includes one strong buy and four buy ratings, with no hold ratings, suggesting consensus optimism. No specific filing, news, or transcript observations are provided to detail recent corporate events or strategic shifts.

Analysts project 18.1% upside to a mean price target of 19.6, reflecting positive market sentiment on valuation.

Net margin of 9.0% is well above the cohort median of 5.3%, highlighting robust profitability relative to industry peers.

The company maintains a low debt-to-equity ratio of 0.29, below the cohort median of 0.40, suggesting conservative leverage.

Revenue declined 18.6% year-over-year in FY2026, signaling a significant contraction in top-line growth momentum.

Long-term debt increased to 1.82 billion CNY in FY2026, up from 1.27 billion CNY in FY2025, increasing leverage risk.

The company faces medium liquidity risk, which could constrain financial flexibility during periods of market stress.

Revenue ¥9.78B, −18,6% YoY; Operating income −11,2% YoY.

• ▍Revenue ¥9.78B, −18,6% YoY
• ▍Operating income −11,2% YoY
• ▍Net income −13,6% YoY
• ▍Free cash flow −53,9% YoY
• ▍Net margin 9.1%

Revenue ¥12.02B, +4,8% YoY; Operating income −0,1% YoY.

• ▍Revenue ¥12.02B, +4,8% YoY
• ▍Operating income −0,1% YoY
• ▍Net income −2,3% YoY
• ▍Free cash flow +23,2% YoY
• ▍Net margin 8.6%

Revenue ¥11.47B, +8,8% YoY; Operating income +19,7% YoY.

• ▍Revenue ¥11.47B, +8,8% YoY
• ▍Operating income +19,7% YoY
• ▍Net income +6,7% YoY
• ▍Free cash flow +17,4% YoY
• ▍Net margin 9.2%

Revenue ¥10.54B, +17,9% YoY; Operating income −9,4% YoY.

• ▍Revenue ¥10.54B, +17,9% YoY
• ▍Operating income −9,4% YoY
• ▍Net income +3,5% YoY
• ▍Free cash flow +63,3% YoY
• ▍Net margin 9.4%

Revenue ¥8.94B; Operating income ¥1.11B.

• ▍Revenue ¥8.94B
• ▍Operating income ¥1.11B
• ▍Net margin 10.7%